Patient Data Supports the Rationale of Low Dose Cyclophosphamide to Potentiate the Anti-Myeloma Activity of Daratumumab through Augmentation of Macrophage-Induced ADCP / Naicker, S., Rigalou, A., Mcellistrim, C., Natoni, A., Chiu, C., Sasser, K., Ryan, A., O'Dwyer, M.. - In: BLOOD. - ISSN 0006-4971. - 130:Supplement 1(2017).
Patient Data Supports the Rationale of Low Dose Cyclophosphamide to Potentiate the Anti-Myeloma Activity of Daratumumab through Augmentation of Macrophage-Induced ADCP
Natoni, AInvestigation
;
2017
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
